X GEN Congress 2013
18 - 20 March, 2013 Hilton San Diego Resort, San Diego, CA, USA


NGS has enabled faster and cheaper mapping of DNA/RNA, allowing genomic comparisons and accelerating genomic discoveries. Cambridge Healthtech Institute is proud to host the Fourth Annual X-Gen Congress and Expo, which is uniquely designed to cover these technological advances and discover advancing applications. With the focus now on clinical utility, find out why data analysis is the driving force that enables discovery, and is sequencing's strategic step.


Plenary Keynote Session


Plenary Keynote Session 

2:00 Chairpersonfs Opening Remarks


2:15 Profiling Dynamic Regulation of the Epigenome Defines Linkages between Metabolism and Breast Cancer

Kevin GardnerKevin Gardner, M.D., Ph.D., Senior Investigator and Head, Transcription Regulation Section, Center for Cancer Research, NCI, NIH, DHHS
New findings linking epigenetic regulation to cellular processes that drive important hallmarks of cancer will be discussed. The broader impact of these findings on defining molecular and genomic mechanisms that uncover important connections between race, obesity and breast cancer will be reviewed.

3:00 Landscape of Somatic Retrotransposition in Human Cancers

Peter ParkPeter J. Park, Ph.D., Associate Professor, Center for Biomedical Informatics, Harvard Medical School; Informatics Program, Childrenfs Hospital Boston
Transposable elements (TEs) comprise close to half of the human genome, and some TE families are still able to copy and insert their sequences into other genomic loci through an RNA-mediated mechanism. We will describe our analysis of somatic retrotransposition events in cancer and their potential role in tumorigenesis, using a computational method called Tea (Transposable Element Analyzer) we developed for detecting TE integration sites at single-nucleotide resolution from paired-end whole-genome sequencing data. We have identified nearly 200 high-confidence somatic TE insertions in the cancer genomes of 43 patients across multiple tumor types, and our integrative analyses with other data types have indicated their potential impact in tumorigenesis. We will give an update on our efforts at characterizing TE activities in a more comprehensive panel of tumor types.

3:45 Afternoon Refreshment Break

4:00 Gene Regulation and Common Disease

John Stamatoyannopoulos, M.D. Associate Professor, Genome Sciences and Medicine, School of Medicine, University of Washington

5:00 Panel Discussion with Plenary Speakers

Kevin DaviesModerator: Kevin A. Davies, Ph.D., Editor-in-Chief, Bio-IT World

Thanks to the explosive power of NGS and extraordinary collaborative projects such as ENCODE and TCGA, researchers are gaining important new insights regarding genome function and architecture, including the role of non-coding RNAs and epigenetic modifications in health and disease. In this plenary panel discussion, our opening speakers will discuss the implications of current research and future directions and priorities.


Monday, March 18, 9:00 am – 12:00 pm

(SC1) NGS Sample Prep

(SC2) Functional Genomics

Tuesday, March 19, 5:30 pm – 8:30 pm

(SC3) Sequencing 101

(SC4) NGS Assembly and Alignment


Co-located Events


Genome in a BottleGenome in a Bottle Consortium

Thursday, March 21

7:30 am Consortium Registration

8:30 Genome in a Bottle Consortium

NIST has recently convened the Genome in a Bottle Consortium to develop the reference materials, reference methods, and reference data needed to support confidence in human whole genome variant calls. The work of this consortium will enable translation of sequencing to clinical applications through a community standards development effort.

The consortium will host a morning session to present its work plan, progress at NIST in developing whole-genome reference materials, and updates from each of four working groups: (1) Reference Material (RM) Selection and Design; (2) Measurements for Reference Material Characterization; (3) Bioinformatics, Data Integration and Data Representation; (4) Performance Metrics and Figures of Merit.

NISTAn open discussion with the working group  chairs  and consortium hosts from NIST will follow the presentations.

NGS for Drugs, Patients and Clinical Trials

March 22-23
Designed for drug developers to explore the unparalleled advantages of NGS technologies for translational research, while addressing common challenges.
Learn more at healthtech.com/ngs-drug-development 


Media Gallery


 

Applying NGS and Data Analysis

Hear first-hand what thought leaders are saying about the use of NGS over the past two years, as well as their perspective on where NGS will take us in the future.

 


 

Detecting Sense-Antisense Transcripts Differentially Regulated by Androgens in Prostate Cancer Cells

Melanie LehmanMelanie Lehman, Ph.D., Research Scientist, Australian Prostate Cancer Research Centre, Queensland University of Technology

To view the poster, please click here.

 

 

2012 DVD

Technologies and Tools for Life Sciences DVD CoverSequencing 101  
In less than five years next-generation sequencing has gone from radical to routine. Naturally, in a field moving so fast, newbies can feel overwhelmed. Sequencing 101 is designed to provide definitions in terminology, types of platforms, workflow strategies, and current applications, to what's next? Learn about the genomic data revolution from data generation to management to analysis and interpretation.
 

 

 

 

Podcasts

gEnding Diagnostic Odysseysh: A Bio-IT World Podcast 

Guest: ELIZABETH WORTHEY PhD, Assistant Professor, Medical College of Wisconsin
Host: KEVIN DAVIES, Editor, Bio-IT World

Elizabeth WortheyA team led by Liz Worthey and Howard Jacob recently published a landmark case report in which genome sequencing of an individual patient, Nicholas Volker, produced a specific diagnosis and a meaningful therapy. Since October 2010, their team at the Medical College of Wisconsin has established a comprehensive review system to end the diagnostic odysseys of other young patients.

In this exclusive podcast, recorded at the Copenhagenomics conference in June 2011, Liz Worthey discusses with Bio-IT World editor Kevin Davies the highs and lows of the Volker case, the challenges of genome data analysis, and how that experience has provided the foundation for ongoing clinical genome sequencing efforts.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Catalog


View All Sponsors 


View Media Partners 

About
NGS Leaders 

 

 

 

 

 


Industry Event Calendar
Search for Biotechnology

Search for Biotechnology

Cambridge Healthtech Institute

Global Information, Inc. - International Marketing Partner of Cambridge Healthtech Institute.